Lista de obras - M Talamonti - Dominio Público Uruguay

HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis

artículo científico publicado en 2020

A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab

artículo científico publicado en 2018

A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab

artículo científico publicado en 2020

A safety evaluation of guselkumab for the treatment of psoriasis

artículo científico publicado en 2018

Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics

artículo científico publicado en 2007

Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients.

artículo científico publicado en 2017

Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis.

artículo científico publicado en 2016

Brodalumab for the treatment of psoriasis

artículo científico publicado en 2016

Characteristic of Chronic Plaque Psoriasis Patients Treated with Biologics in Italy during the COVID-19 Pandemic: Risk Analysis from the PSO-BIO-COVID Observational Study

artículo científico publicado en 2020

Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature

artículo científico publicado en 2020

Continuous treatment of plaque-type psoriasis with etanercept: an observational long-term experience

scientific article published on 01 April 2010

Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations.

artículo científico publicado en 2014

Efalizumab

scientific article published on 10 January 2011

Effect of Secukinumab on Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: a Post hoc Analysis of the SUPREME Study

scientific article published on 03 December 2020

Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients

artículo científico publicado en 2017

Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study

artículo científico publicado en 2018

Efficacy of Short-Term Cyclosporine Treatment to Control Psoriasis-Related Events during Efalizumab Therapy

Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.

artículo científico publicado en 2009

Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis

scientific article published on 28 January 2015

Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study

artículo científico publicado en 2012

Genetic variations in IL6 and IL12B decreasing the risk for psoriasis.

artículo científico publicado en 2013

HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.

artículo científico publicado en 2016

HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study

artículo científico publicado en 2017

HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis

artículo científico publicado en 2016

IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.

artículo científico publicado en 2015

Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies

scientific article published on 27 November 2020

In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis

artículo científico publicado en 2019

Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis.

artículo científico publicado en 2017

Linear psoriasis following the typical distribution of the sciatic nerve.

artículo científico publicado en 2015

Long-term efficacy of adalimumab in generalized pustular psoriasis.

artículo científico publicado en 2008

Long-term treatment of plaque psoriasis with efalizumab: an Italian experience

article

Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature

artículo científico publicado en 2015

Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris.

artículo científico publicado en 2013

Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?

artículo científico publicado en 2020

Patients with Moderate to Severe Plaque Psoriasis: One Year after the European Medicines Agency Recommendation of Efalizumab Suspension

scientific article published on 13 April 2011

Pharmacogenetics of psoriasis:HLA-Cw6but notLCE3B/3Cdeletion norTNFAIP3polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab

article

Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis

artículo científico publicado en 2017

Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections

artículo científico publicado en 2017

Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab

article

Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.

artículo científico publicado en 2017

Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation

artículo científico publicado en 2018

Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo

artículo científico publicado en 2020

Skin immunity and its dysregulation in psoriasis

scientific article published on 15 August 2019

Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era

artículo científico publicado en 2020

The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature.

artículo científico publicado en 2017

The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab

artículo científico publicado en 2010

Tildrakizumab for treating psoriasis.

artículo científico publicado en 2017

Tofacitinib for the treatment of psoriasis

artículo científico publicado en 2016

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study

scientific article published on 09 July 2020

Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome.

artículo científico publicado en 2012

Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases.

scientific article published on 26 September 2013

What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice.

artículo científico publicado en 2014

Lista de obras de M Talamonti

<i>HLA-Cw6</i> and other HLA-C alleles, as well as <i>MICB-DT, DDX58</i> and <i>TYK2</i> genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis

A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab

A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab

A safety evaluation of guselkumab for the treatment of psoriasis

Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics

Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients.

Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis.

Brodalumab for the treatment of psoriasis

Characteristic of Chronic Plaque Psoriasis Patients Treated with Biologics in Italy during the COVID-19 Pandemic: Risk Analysis from the PSO-BIO-COVID Observational Study

Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature

Continuous treatment of plaque-type psoriasis with etanercept: an observational long-term experience

Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations.

Efalizumab

Effect of Secukinumab on Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: a Post hoc Analysis of the SUPREME Study

Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients

Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study

Efficacy of Short-Term Cyclosporine Treatment to Control Psoriasis-Related Events during Efalizumab Therapy

Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.

Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis

Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study

Genetic variations in IL6 and IL12B decreasing the risk for psoriasis.

HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.

HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study

HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis

IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.

Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies

In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis

Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis.

Linear psoriasis following the typical distribution of the sciatic nerve.

Long-term efficacy of adalimumab in generalized pustular psoriasis.

Long-term treatment of plaque psoriasis with efalizumab: an Italian experience

Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature

Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris.

Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?

Patients with Moderate to Severe Plaque Psoriasis: One Year after the European Medicines Agency Recommendation of Efalizumab Suspension

Pharmacogenetics of psoriasis:HLA-Cw6but notLCE3B/3Cdeletion norTNFAIP3polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab

Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis

Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections

Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab

Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.

Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation

Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo

Skin immunity and its dysregulation in psoriasis

Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era

The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature.

The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab

Tildrakizumab for treating psoriasis.

Tofacitinib for the treatment of psoriasis

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study

Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome.

Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases.

What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice.